467 related articles for article (PubMed ID: 29108428)
1. The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study.
Wan YM; Li YH; Xu ZY; Wu HM; Xu Y; Yang M; Wu XN
Integr Cancer Ther; 2018 Jun; 17(2):477-485. PubMed ID: 29108428
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma.
Zhao H; Zhai X; Chen Z; Wan X; Chen L; Shen F; Ling C
Oncotarget; 2017 Jul; 8(28):45234-45241. PubMed ID: 28423370
[TBL] [Abstract][Full Text] [Related]
3. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
[TBL] [Abstract][Full Text] [Related]
8. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?
Celsa C; Cabibbo G; Enea M; Battaglia S; Rizzo GEM; Busacca A; Giuffrida P; Stornello C; Brancatelli G; Cannella R; Gruttadauria S; Cammà C
Liver Int; 2021 May; 41(5):1105-1116. PubMed ID: 33587814
[TBL] [Abstract][Full Text] [Related]
9. Prognostic analysis of transarterial chemoembolization combined with a traditional Chinese herbal medicine formula for treatment of unresectable hepatocellular carcinoma.
Yu Y; Lang QB; Chen Z; Li B; Yu CQ; Zhu DZ; Huang XQ; Zhai XF; Ling CQ
Chin Med J (Engl); 2009 Sep; 122(17):1990-5. PubMed ID: 19781383
[TBL] [Abstract][Full Text] [Related]
10. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.
Zheng L; Li HL; Guo CY; Luo SX
Korean J Radiol; 2018; 19(2):237-246. PubMed ID: 29520181
[TBL] [Abstract][Full Text] [Related]
12. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population.
Lee SW; Tung CF; Peng YC; Lien HC; Chang CS
J Dig Dis; 2020 Aug; 21(8):462-467. PubMed ID: 32472590
[TBL] [Abstract][Full Text] [Related]
14. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma.
Dettmer A; Kirchhoff TD; Gebel M; Zender L; Malek NP; Panning B; Chavan A; Rosenthal H; Kubicka S; Krusche S; Merkesdal S; Galanski M; Manns MP; Bleck JS
World J Gastroenterol; 2006 Jun; 12(23):3707-15. PubMed ID: 16773687
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Chen J; Zhou C; Long Y; Yin X
Tumour Biol; 2015 Jan; 36(1):183-91. PubMed ID: 25217986
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
Li JH; Xie XY; Zhang L; Le F; Ge NL; Li LX; Gan YH; Chen Y; Zhang JB; Xue TC; Chen RX; Xia JL; Zhang BH; Ye SL; Wang YH; Ren ZG
World J Gastroenterol; 2015 Apr; 21(13):3970-7. PubMed ID: 25852283
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.
Kim JY; Sinn DH; Gwak GY; Choi GS; Saleh AM; Joh JW; Cho SK; Shin SW; Carriere KC; Ahn JH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Clin Mol Hepatol; 2016 Jun; 22(2):250-8. PubMed ID: 27377909
[TBL] [Abstract][Full Text] [Related]
19. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.
Xu LF; Sun HL; Chen YT; Ni JY; Chen D; Luo JH; Zhou JX; Hu RM; Tan QY
J Gastroenterol Hepatol; 2013 Mar; 28(3):456-63. PubMed ID: 23216261
[TBL] [Abstract][Full Text] [Related]
20. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
